Role of Neuropilin-1 and its expression in Egyptian Acute Myeloid and Acute Lymphoid Leukemia patients

Younan, Sarah A.; Elhoseiny, Shereen Mohamed; Hammam, Amira Ahmed; Gawdat, Rania M.; El-Wakil, Mohamed; Fawzy, Mohamed

doi:10.1016/j.leukres.2011.08.017

Cited by 14 publications

(10 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, the proportion of CD4 + CD25 + FoxP3 + Treg cells and expression of NRP‐1 on Tregs both increased, as did mRNA and plasma levels of NRP‐1, in our acute leukemia patients. These results are consistent with the findings of previous studies (Younan et al ., ; Piechnik et al ., ; Yang and Xu ), and they also suggest that overexpression of NRP‐1 and Tregs contributes to the pathogenesis of acute leukemia. Furthermore, an increased proportion of Tregs may facilitate leukemogenesis by suppressing the activation of immune cells and weakening the anti‐tumor immune response.…”

Section: Discussionmentioning

confidence: 97%

The Neuropilin‐1 Ligand, Sema3A, Acts as a Tumor Suppressor in the Pathogenesis of Acute Leukemia

Yang

Wen

et al. 2018

The Anatomical Record

View full text Add to dashboard Cite

Semaphorin‐3A (Sema3A) and vascular endothelial growth factor (VEGF165) are ligands of neuropilin‐1 (NRP‐1 or CD304) and are related to immunoregulation and tumor angiogenesis, respectively. However, possible interactions between NRP‐1 and Sema3A and VEGF165 in acute leukemia remain unclear, especially whether Sema3A plays a role in acute leukemia. In this study, both of the proportion of regulatory T cells (Tregs) and their expression of NRP‐1 were found to increase in acute leukemia patients compared with healthy controls. In contrast, lower mRNA and plasma levels of Sema3A were detected in the acute leukemia patients. In vitro, the addition of exogenous Sema3A inhibited the expression of NRP‐1 on Tregs and it promoted apoptosis of leukemia cells. However, in the presence of anti‐Sema3A antibody, the effect of rhSema3A on NRP‐1 expression was reversed. These results suggest that Sema3A promotes apoptosis in leukemia cells by inhibiting expression of NRP‐1, and thus, represents a tumor suppressor protein with a role in the pathogenesis of acute leukemia. Consequently, NRP‐1/Sema3A signaling may represent a novel target for the treatment of acute leukemia and should be further studied. Anat Rec, 302:1127–1135, 2019. © 2018 Wiley Periodicals, Inc.

show abstract

Section: Discussionmentioning

confidence: 97%

The Neuropilin‐1 Ligand, Sema3A, Acts as a Tumor Suppressor in the Pathogenesis of Acute Leukemia

Yang

Wen

et al. 2018

The Anatomical Record

View full text Add to dashboard Cite

show abstract

“…5-13.5) and display completely disorganized vascular networks [10]. NRP-1 has been found widely distributed in adult tissues with low expression [11] but significantly increases in various tumors such as glioma [12], pancreatic [13], gastric [14], colon [15,16], breast [17,18], and non-small-cell lung cancers [19] and in acute myeloid leukemia [20,21]. Increased expression of NRP-1 is significantly associated with poor outcomes in breast [18], colon [16], and non-small-cell lung cancer [19] patients, and is correlated with invasivity and metastatic potential in glioma [22] and gastrointestinal [23] and prostate carcinomas [24], which suggests that NRP-1 expression could be used as a diagnostic and prognostic marker for these tumors.…”

Section: Introductionmentioning

confidence: 99%

A monoclonal antibody targeting neuropilin-1 inhibits adhesion of MCF7 breast cancer cells to fibronectin by suppressing the FAK/p130cas signaling pathway

Zeng

Luo

et al. 2014

Anti-Cancer Drugs

View full text Add to dashboard Cite

Neuropilin-1 (NRP-1) is a nontyrosine kinase coreceptor for semaphorin 3A and the vascular endothelial growth factor involved in tumor angiogenesis, growth, and metastasis and is regarded as a promising target for cancer therapy. In the present study, we investigated the effects of an anti-NRP-1 monoclonal antibody (mAb) that we generated for MCF7 breast cancer cellular adhesion studies. MTT, colony formation, and adhesion assays showed that our anti-NRP-1 mAb dose-dependently inhibited MCF7 proliferation and fibronectin adhesion, leading to a rounded cellular morphology. Further, rhodamine phalloidin stain revealed that fibronectin-dependent formation of actin stress fibers was inhibited by anti-NRP-1 mAb. Immunoprecipitation and western blot showed that anti-NRP-1 mAb treatment inhibited the formation of NRP-1-α5β1 integrin complexes and suppressed the phosphorylation of focal adhesion kinase and p130cas in MCF7 cells. These findings contribute to further understanding the NRP-1 function in cell adhesion and tumor metastasis. Moreover, our anti-NRP-1 mAb is a prospective drug candidate for tumor treatment.

show abstract

“…In a study by Younan et al [15] on Egyptian AML patients using real-time quantitative RT-PCR, it was revealed that NRP-1 was expressed in 95% of AML cases with levels higher in patients than controls, and there was a statistically significant difference in NRP-1 levels between patients who went into complete remission and those who did not. They concluded that NRP-1 is significantly associated with acute leukemia and that its level might serve as an indicator for disease severity and progression.…”

Section: Discussionmentioning

confidence: 99%

Significance of Neuropilin-1 Expression in Acute Myeloid Leukemia

Sallam¹,

Telbany²,

Mahmoud³

et al. 2013

Tjh

View full text Add to dashboard Cite

Objective: Neuropilin-1 is a vascular endothelial growth factor receptor that acts as a mediator of angiogenesis. Its importance in hematological malignancies such as acute myeloid leukemia (AML) remains to be elucidated. The aim of this study was to evaluate the significance of neuropilin-1 expression in AML patients by both flow cytometry and real-time polymerase chain reaction (PCR) in regard to its diagnostic and prognostic values. Materials and Methods: Bone marrow aspirates of 44 patients with de novo AML and 12 relapsed AML patients were examined in this study. Ten subjects with nonhematological malignancy serving as the control group were also included. Results: Neuropilin-1 expression by flow cytometry showed a highly significant increase in de novo and relapsed AML patients with a mean of 27.1±17.5% and 21.5±16.6%, respectively, compared to control group’s mean of 3.4±1.9%. A cut-off value of 6% was established as differentiating patients from the control group. By real-time PCR, no statistical significance was found in de novo and relapsed AML patients with a mean of 1.9±3.6 IU/L and 0.3±0.2 IU/L, respectively, compared to the control group’s mean of 0.3±0.1 IU/L. Neuropilin-1 surface expression by flow cytometry showed a significant correlation with total leukocyte count and a negative correlation with hemoglobin level in de novo AML patients. In relapsed AML patients, positive significant correlations were found with age, bone marrow blast percentage, and CD14. Neuropilin-1 mRNA level by real-time PCR showed a positive significant correlation with peripheral blood blast percentage and CD117 and a negative correlation with hemoglobin level in de novo AML patients. In relapsed patients, a positive correlation was found with lactate dehydrogenase. Conclusion: Neuropilin-1 can be used as a tool for diagnosis and prognosis in AML patients. Conflict of interest:None declared.

show abstract

Role of Neuropilin-1 and its expression in Egyptian Acute Myeloid and Acute Lymphoid Leukemia patients

Cited by 14 publications

References 32 publications

The Neuropilin‐1 Ligand, Sema3A, Acts as a Tumor Suppressor in the Pathogenesis of Acute Leukemia

The Neuropilin‐1 Ligand, Sema3A, Acts as a Tumor Suppressor in the Pathogenesis of Acute Leukemia

A monoclonal antibody targeting neuropilin-1 inhibits adhesion of MCF7 breast cancer cells to fibronectin by suppressing the FAK/p130cas signaling pathway

Significance of Neuropilin-1 Expression in Acute Myeloid Leukemia

Contact Info

Product

Resources

About